Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Antimalarial benzoheterocyclic 4-aminoquinolines: Structure-activity relationship, in vivo evaluation, mechanistic and bioactivation studies.

Ongarora DS, Strydom N, Wicht K, Njoroge M, Wiesner L, Egan TJ, Wittlin S, Jurva U, Masimirembwa CM, Chibale K.

Bioorg Med Chem. 2015 Sep 1;23(17):5419-32. doi: 10.1016/j.bmc.2015.07.051. Epub 2015 Jul 30.

PMID:
26264839
2.
3.

Benzoheterocyclic amodiaquine analogues with potent antiplasmodial activity: synthesis and pharmacological evaluation.

Ongarora DS, Gut J, Rosenthal PJ, Masimirembwa CM, Chibale K.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):5046-50. doi: 10.1016/j.bmcl.2012.06.010. Epub 2012 Jun 9.

PMID:
22749280
4.

Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the broad spectrum antimicrobial herbal extract from P. fruticosa.

Thelingwani RS, Dhansay K, Smith P, Chibale K, Masimirembwa CM.

Xenobiotica. 2012 Oct;42(10):989-1000. doi: 10.3109/00498254.2012.681077. Epub 2012 Apr 25.

PMID:
22533317
5.

Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan.

Bonn B, Masimirembwa CM, Castagnoli N Jr.

Drug Metab Dispos. 2010 Jan;38(1):187-99. doi: 10.1124/dmd.109.028670.

PMID:
19797609
6.

In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions.

Thelingwani RS, Zvada SP, Dolgos H, Ungell AL, Masimirembwa CM.

Drug Metab Dispos. 2009 Jun;37(6):1286-94. doi: 10.1124/dmd.108.024604. Epub 2009 Mar 19.

PMID:
19299526
7.

The molecular basis of CYP2D6-mediated N-dealkylation: balance between metabolic clearance routes and enzyme inhibition.

Bonn B, Masimirembwa CM, Aristei Y, Zamora I.

Drug Metab Dispos. 2008 Nov;36(11):2199-210. doi: 10.1124/dmd.108.022376. Epub 2008 Aug 25.

PMID:
18725510
8.

Establishment of a biobank and pharmacogenetics database of African populations.

Matimba A, Oluka MN, Ebeshi BU, Sayi J, Bolaji OO, Guantai AN, Masimirembwa CM.

Eur J Hum Genet. 2008 Jul;16(7):780-3. doi: 10.1038/ejhg.2008.49. Epub 2008 Apr 2. No abstract available.

9.

Recommendations of the 2006 Human Variome Project meeting.

Cotton RG; 2006 Human Variome Project, Appelbe W, Auerbach AD, Becker K, Bodmer W, Boone DJ, Boulyjenkov V, Brahmachari S, Brody L, Brookes A, Brown AF, Byers P, Cantu JM, Cassiman JJ, Claustres M, Concannon P, Cotton RG, den Dunnen JT, Flicek P, Gibbs R, Hall J, Hasler J, Katz M, Kwok PY, Laradi S, Lindblom A, Maglott D, Marsh S, Masimirembwa CM, Minoshima S, de Ramirez AM, Pagon R, Ramesar R, Ravine D, Richards S, Rimoin D, Ring HZ, Scriver CR, Sherry S, Shimizu N, Stein L, Tadmouri GO, Taylor G, Watson M.

Nat Genet. 2007 Apr;39(4):433-6.

PMID:
17392799
10.

Exploration of enzyme-ligand interactions in CYP2D6 & 3A4 homology models and crystal structures using a novel computational approach.

Kjellander B, Masimirembwa CM, Zamora I.

J Chem Inf Model. 2007 May-Jun;47(3):1234-47. Epub 2007 Mar 24.

PMID:
17381082
11.

Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans.

Persson KP, Ekehed S, Otter C, Lutz ES, McPheat J, Masimirembwa CM, Andersson TB.

Pharm Res. 2006 Jan;23(1):56-69. Epub 2006 Nov 22.

PMID:
16328606
12.

Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.

Bapiro TE, Sayi J, Hasler JA, Jande M, Rimoy G, Masselle A, Masimirembwa CM.

Eur J Clin Pharmacol. 2005 Nov;61(10):755-61. Epub 2005 Oct 29.

PMID:
16261361
13.

Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques.

Afzelius L, Raubacher F, Karlén A, Jørgensen FS, Andersson TB, Masimirembwa CM, Zamora I.

Drug Metab Dispos. 2004 Nov;32(11):1218-29.

PMID:
15483192
14.

Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.

Afzelius L, Zamora I, Masimirembwa CM, Karlén A, Andersson TB, Mecucci S, Baroni M, Cruciani G.

J Med Chem. 2004 Feb 12;47(4):907-14.

PMID:
14761192
15.

Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.

Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM.

Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12.

PMID:
12920490
16.

Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.

Masimirembwa CM, Bredberg U, Andersson TB.

Clin Pharmacokinet. 2003;42(6):515-28. Review.

PMID:
12793837
17.

Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C>T and 590G>A.

Dandara C, Masimirembwa CM, Magimba A, Kaaya S, Sayi J, Sommers DK, Snyman JR, Hasler JA.

Pharmacogenetics. 2003 Jan;13(1):55-8.

PMID:
12544513
18.

Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors.

Afzelius L, Masimirembwa CM, Karlén A, Andersson TB, Zamora I.

J Comput Aided Mol Des. 2002 Jul;16(7):443-58.

PMID:
12510879
19.

Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells.

Bapiro TE, Andersson TB, Otter C, Hasler JA, Masimirembwa CM.

Eur J Clin Pharmacol. 2002 Nov;58(8):537-42. Epub 2002 Oct 2.

PMID:
12451431
20.

Genetic polymorphism of cytochrome P450 1A1 (Cyp1A1) and glutathione transferases (M1, T1 and P1) among Africans.

Dandara C, Sayi J, Masimirembwa CM, Magimba A, Kaaya S, De Sommers K, Snyman JR, Hasler JA.

Clin Chem Lab Med. 2002 Sep;40(9):952-7.

PMID:
12435115
21.

Combining pharmacophore and protein modeling to predict CYP450 inhibitors and substrates.

Masimirembwa CM, Ridderström M, Zamora I, Andersson TB.

Methods Enzymol. 2002;357:133-44. No abstract available.

PMID:
12424905
22.

Monolithic silica rod liquid chromatography with ultraviolet or fluorescence detection for metabolite analysis of cytochrome P450 marker reactions.

Lutz ES, Markling ME, Masimirembwa CM.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):205-15.

PMID:
12401345
24.

Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.

Li XQ, Björkman A, Andersson TB, Ridderström M, Masimirembwa CM.

J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.

PMID:
11805197
25.

In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery.

Masimirembwa CM, Thompson R, Andersson TB.

Comb Chem High Throughput Screen. 2001 May;4(3):245-63. Review.

PMID:
11375740
26.

Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.

Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, Sommers DK, Snyman JR, Hasler JA.

Eur J Clin Pharmacol. 2001 Apr;57(1):11-7.

PMID:
11372584
27.

Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis.

Afzelius L, Zamora I, Ridderström M, Andersson TB, Karlén A, Masimirembwa CM.

Mol Pharmacol. 2001 Apr;59(4):909-19.

PMID:
11259637
28.

Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.

Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM.

Drug Metab Dispos. 2001 Jan;29(1):30-5.

PMID:
11124226
29.

Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research.

Masimirembwa CM, Otter C, Berg M, Jönsson M, Leidvik B, Jonsson E, Johansson T, Bäckman A, Edlund A, Andersson TB.

Drug Metab Dispos. 1999 Oct;27(10):1117-22.

PMID:
10497136
30.

Molecular epidemiology of Plasmodium falciparum antifolate resistance in Vietnam: genotyping for resistance variants of dihydropteroate synthase and dihydrofolate reductase.

Masimirembwa CM, Phuong-dung N, Phuc BQ, Duc-Dao L, Sy ND, Sköld O, Swedberg G.

Int J Antimicrob Agents. 1999 Aug;12(3):203-11.

PMID:
10461838
31.

Genetic polymorphism of cytochrome P4501A1, microsomal epoxide hydrolase, and glutathione S-transferases M1 and T1 in Zimbabweans and Venda of southern Africa.

Masimirembwa CM, Dandara C, Sommers DK, Snyman JR, Hasler JA.

Pharmacogenetics. 1998 Feb;8(1):83-5. No abstract available.

PMID:
9511185
32.
33.
34.

Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes.

Masimirembwa CM, Gustafsson LL, Dahl ML, Abdi YA, Hasler JA.

Br J Clin Pharmacol. 1996 Apr;41(4):344-6.

35.

Low CYP1A2 activity in rural Shona children of Zimbabwe.

Masimirembwa CM, Beke M, Hasler JA, Tang BK, Kalow W.

Clin Pharmacol Ther. 1995 Jan;57(1):25-31.

PMID:
7828378
36.

Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.

Masimirembwa CM, Hasler JA, Johansson I.

Eur J Clin Pharmacol. 1995;48(1):35-8.

PMID:
7621845
37.

Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors.

Masimirembwa CM, Hasler JA.

Biochem Pharmacol. 1994 Nov 1;48(9):1779-83.

PMID:
7980647
38.

The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans.

Masimirembwa CM, Naik YS, Hasler JA.

Biopharm Drug Dispos. 1994 Jan;15(1):33-43.

PMID:
8161714
39.

Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.

Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M.

Pharmacogenetics. 1993 Dec;3(6):275-80.

PMID:
7908586
40.

Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics of praziquantel in rats.

Masimirembwa CM, Naik YS, Hasler JA.

Eur J Drug Metab Pharmacokinet. 1993 Jul-Sep;18(3):261-4.

PMID:
8149944

Supplemental Content

Loading ...
Support Center